BioSpace News Archive

ZAP Surgical Systems, Inc. today announced that Centre de Cancérologie de la Porte de Saint-Cloud (CCPSC) in Boulogne, France, has initiated patient treatments with the ground-breaking ZAP-X® Gyroscopic Radiosurgery® platform.

BrainsWay Ltd. today announced the appointment of Ido Marom, an experienced senior financial leader in global industries, including medical technology, as Chief Financial Officer (CFO).

Quipt Home Medical Corp., a U.S. based home medical equipment provider, focused on end-to-end respiratory care, is very pleased to announce it is on a preliminary list dated May 19, 2023 issued by FTSE Russell to join the Russell 2000® and 3000® Indexes at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. market opens on June 26, 2023.

Kura Oncology, Inc. today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in the following events at upcoming investor conferences.

Aclarion, Inc. announced that Dean Karahalios, M.D., Medical Director of Brain & Spine Institute at Advocate Aurora Health Care in Illinois, will advise the company as a key opinion leader nationally.

Cognition Therapeutics, Inc. , (Nasdaq: CGTX), (the “Company” or “Cognition”) has released its fifth “Conversations” video podcast, a review and interactive discussion of Cognition’s CT1812 biomarker results presented at AD/PD™ 2023, the Alzheimer’s & Parkinson’s Diseases Conference.

Wave Life Sciences Ltd. today announced topline results from the Phase 1b/2a FOCUS-C9 study evaluating WVE-004 as an investigational treatment for C9orf72-associated amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) (C9-ALS/FTD).

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the Company’s T2Biothreat™ Panel.

Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN) today announced that the Company will present at the 2023 BIO International Convention taking place in Boston, Mass. from June 5-8, 2023.

Cogent Biosciences, Inc. today announced the details of its investor webcast being held Monday, June 5, 2023 at 8:00 a.m. ET (7:00 a.m. CT) to discuss lead-in data from its ongoing Phase 3 PEAK trial evaluating bezuclastinib in combination with sunitinib in patients with Gastrointestinal Stromal Tumors (GIST).